The efficacy of CB-103, a first-in-class transcriptional Notch inhibitor, in preclinical models of breast cancer https://www.biorxiv.org/content/10.1101/2023.07.06.547830v1?med=mas
The efficacy of CB-103, a first-in-class transcriptional Notch inhibitor, in preclinical models of breast cancer https://www.biorxiv.org/content/10.1101/2023.07.06.547830v1?med=mas